CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities–Merits and Challenges
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities–Merits and Challenges
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 23, Pages 5942
Publisher
MDPI AG
Online
2019-11-26
DOI
10.3390/ijms20235942
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HER2 CAR-T cells eradicate uveal melanoma and T cell therapy-resistant human melanoma in interleukin-2 (IL-2) transgenic NOD/SCID IL-2 receptor knockout mice
- (2019) Elin MV Forsberg et al. CANCER RESEARCH
- NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
- (2019) Belen Lopez-Millan et al. LEUKEMIA
- Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma
- (2019) Stephanie L. Goff et al. JOURNAL OF IMMUNOTHERAPY
- Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T‐cell therapy for chronic lymphocytic leukemia
- (2019) Steven M. Bair et al. AMERICAN JOURNAL OF HEMATOLOGY
- Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T cell efficacy
- (2019) Jaco A. C. van Bruggen et al. BLOOD
- Furanodienone overcomes temozolomide resistance in glioblastoma through the downregulation of CSPG4‐Akt‐ERK signalling by inhibiting EGR1‐dependent transcription
- (2019) Lei Chen et al. PHYTOTHERAPY RESEARCH
- Proteoglycans and glycosaminoglycans as regulators of cancer stem cell function and therapeutic resistance
- (2019) Daiana Vitale et al. FEBS Journal
- Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?
- (2019) Katherine D. Cummins et al. HAEMATOLOGICA
- CAR T cells for brain tumors: Lessons learned and road ahead
- (2019) David Akhavan et al. IMMUNOLOGICAL REVIEWS
- The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells
- (2019) Michael Bachmann IMMUNOLOGY LETTERS
- CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia
- (2019) Dennis C. Harrer et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
- (2019) Bryan D. Choi et al. NATURE BIOTECHNOLOGY
- CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
- (2019) Ru Zhou et al. Frontiers in Immunology
- Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance
- (2019) Manuel Wiesinger et al. Cancers
- Determinants of response and resistance to CAR T cell therapy
- (2019) Stefanie Lesch et al. SEMINARS IN CANCER BIOLOGY
- Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia
- (2018) Miriam Y. Kim et al. CELL
- A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers
- (2018) Jing Wei et al. CELLULAR IMMUNOLOGY
- BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy
- (2018) Jan Dörrie et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells
- (2018) Yali Han et al. Journal of Hematology & Oncology
- CAR T-cells targeting FLT3 have potent activity against FLT3−ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib
- (2018) Hardikkumar Jetani et al. LEUKEMIA
- Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
- (2018) S. Haubner et al. LEUKEMIA
- Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors
- (2018) Erhao Zhang et al. Molecular Cancer
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
- (2018) Joseph A. Fraietta et al. NATURE MEDICINE
- CAR T-Cell Therapy in Large B-Cell Lymphoma
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy
- (2018) Serena Pellegatta et al. Science Translational Medicine
- Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types
- (2018) Kristina M. Ilieva et al. Frontiers in Immunology
- Abstract CT131: A phase I study of adoptive immunotherapy for advanced ROR1+ malignancies with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR)
- (2018) Jennifer M. Specht et al. CANCER RESEARCH
- The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas
- (2018) Davide Schiffer et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Tumors evading CARs—the chase is on
- (2018) Sarwish Rafiq et al. NATURE MEDICINE
- Differential Expression of Cancer-Associated Fibroblast-Related Proteins in Ductal Carcinoma in situ According to Molecular Subtype and Stromal Histology
- (2018) Ji Hee Lee et al. PATHOBIOLOGY
- Teaching an old dog new tricks: next-generation CAR T cells
- (2018) Nicholas Tokarew et al. BRITISH JOURNAL OF CANCER
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology
- (2018) Keisuke Watanabe et al. Frontiers in Immunology
- Bevacizumab and risk of intracranial hemorrhage in patients with brain metastases: a meta-analysis
- (2017) Lin Yang et al. JOURNAL OF NEURO-ONCOLOGY
- NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL
- (2017) C Prieto et al. LEUKEMIA
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
- (2017) Donald M. O’Rourke et al. Science Translational Medicine
- Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
- (2017) Julia Tchou et al. Cancer Immunology Research
- MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches
- (2017) Amanda C. Winters et al. Frontiers in Pediatrics
- Chimeric antigen receptor T cells targeting Fc receptor selectively eliminate CLL cells while sparing healthy B cells
- (2016) E. Faitschuk et al. BLOOD
- Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
- (2016) Kole T. Roybal et al. CELL
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
- (2016) Avery D. Posey et al. IMMUNITY
- Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
- (2016) Carlos A. Ramos et al. JOURNAL OF CLINICAL INVESTIGATION
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mesenchymal Tumors Can Derive from Ng2/Cspg4-Expressing Pericytes with β-Catenin Modulating the Neoplastic Phenotype
- (2016) Shingo Sato et al. Cell Reports
- Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy
- (2016) Fabiana Perna et al. Translational Cancer Research
- Melanoma-expressed CD70 is involved in invasion and metastasis
- (2015) Christine Pich et al. BRITISH JOURNAL OF CANCER
- Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone
- (2015) Christian Krug et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Bioactivity and Safety of IL13R 2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
- (2015) C. E. Brown et al. CLINICAL CANCER RESEARCH
- BRAF and MEK Inhibition Variably Affect GD2-specific Chimeric Antigen Receptor (CAR) T-Cell Function In Vitro
- (2015) Tessa Gargett et al. JOURNAL OF IMMUNOTHERAPY
- CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
- (2015) S S Kenderian et al. LEUKEMIA
- Remote control of therapeutic T cells through a small molecule-gated chimeric receptor
- (2015) C.-Y. Wu et al. SCIENCE
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- Theranostic Impact of NG2/CSPG4 Proteoglycan in Cancer
- (2015) Pier Andrea Nicolosi et al. Theranostics
- Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells
- (2015) Max Schlaak et al. Oncotarget
- Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
- (2014) S. Gill et al. BLOOD
- Reduced promoter methylation and increased expression of CSPG4 negatively influences survival of HNSCC patients
- (2014) Rolf Warta et al. INTERNATIONAL JOURNAL OF CANCER
- Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+T Cells
- (2014) Keisuke Watanabe et al. JOURNAL OF IMMUNOLOGY
- Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival
- (2014) Gary Tozbikian et al. PLoS One
- Oligodendrocyte Precursor Cells Modulate the Neuronal Network by Activity-Dependent Ectodomain Cleavage of Glial NG2
- (2014) Dominik Sakry et al. PLOS BIOLOGY
- Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells
- (2014) Rachel E Beard et al. Journal for ImmunoTherapy of Cancer
- NG2 proteoglycan promotes tumor vascularization via integrin-dependent effects on pericyte function
- (2013) Weon-Kyoo You et al. ANGIOGENESIS
- High chondroitin sulfate proteoglycan 4 expression correlates with poor outcome in patients with breast cancer
- (2013) Nicholas C. Hsu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
- (2013) G. P. Linette et al. BLOOD
- T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo
- (2013) C. Geldres et al. CLINICAL CANCER RESEARCH
- Gene Expression Profiling using Nanostring Digital RNA Counting to Identify Potential Target Antigens for Melanoma Immunotherapy
- (2013) R. E. Beard et al. CLINICAL CANCER RESEARCH
- Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia
- (2013) David S. Ritchie et al. MOLECULAR THERAPY
- Antibody–drug conjugates: targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin
- (2013) Elisabetta Falvo et al. Nanoscale
- The chrondroitin sulfate proteoglycan (CSPG4) regulates human trophoblast function
- (2013) M. Van Sinderen et al. PLACENTA
- PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
- (2013) V. D. Fedorov et al. Science Translational Medicine
- NG2/CSPG4-collagen type VI interplays putatively involved in the microenvironmental control of tumour engraftment and local expansion
- (2013) S. Cattaruzza et al. Journal of Molecular Cell Biology
- Mesothelin, a novel immunotherapy target for triple negative breast cancer
- (2012) Julia Tchou et al. BREAST CANCER RESEARCH AND TREATMENT
- Stem-like Tumor-Initiating Cells Isolated from IL13R 2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakine-Redirected T Cells
- (2012) C. E. Brown et al. CLINICAL CANCER RESEARCH
- Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
- (2012) Christopher C Kloss et al. NATURE BIOTECHNOLOGY
- Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma
- (2011) Agnete Svendsen et al. ACTA NEUROPATHOLOGICA
- In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor
- (2011) G. M. P. Giordano Attianese et al. BLOOD
- Functional Characterization of an scFv-Fc Antibody that Immunotherapeutically Targets the Common Cancer Cell Surface Proteoglycan CSPG4
- (2011) X. Wang et al. CANCER RESEARCH
- The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells
- (2011) Ling Yu et al. IMMUNOLOGIC RESEARCH
- Interleukin-8 derived from local tissue-resident stromal cells promotes tumor cell invasion
- (2011) Gabriel Welte et al. MOLECULAR CARCINOGENESIS
- CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma
- (2011) Matthew A. Price et al. Pigment Cell & Melanoma Research
- Targeting the NG2/CSPG4 Proteoglycan Retards Tumour Growth and Angiogenesis in Preclinical Models of GBM and Melanoma
- (2011) Jian Wang et al. PLoS One
- Eradication of melanomas by targeted elimination of a minor subset of tumor cells
- (2011) P. Schmidt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor
- (2010) M. Hudecek et al. BLOOD
- Anti-GD3 Chimeric sFv-CD28/T-Cell Receptor Designer T Cells for Treatment of Metastatic Melanoma and Other Neuroectodermal Tumors
- (2010) A. S. Y. Lo et al. CLINICAL CANCER RESEARCH
- Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice
- (2010) Dhanalakshmi Chinnasamy et al. JOURNAL OF CLINICAL INVESTIGATION
- CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer
- (2010) Xinhui Wang et al. JNCI-Journal of the National Cancer Institute
- Genomic instability in breast cancer: Pathogenesis and clinical implications
- (2010) Kevin A. Kwei et al. Molecular Oncology
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- Melanoma Proteoglycan Modifies Gene Expression to Stimulate Tumor Cell Motility, Growth, and Epithelial-to-Mesenchymal Transition
- (2009) J. Yang et al. CANCER RESEARCH
- Interaction of Syntenin-1 and the NG2 Proteoglycan in Migratory Oligodendrocyte Precursor Cells
- (2008) Nivedita Chatterjee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling
- (2008) M Chekenya et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started